Antibodies to Infliximab and Adalimumab in Patients with Rheumatoid Arthritis in Clinical Remission: A Cross-Sectional Study

Table 1

Demographic characteristics of study cohort at time of inclusion and blood sampling.

	Infliximab; n = 44	Adalimumab; n = 49
Age, years	63 (52–71)	54 (46–68)	0.033
Female gender, (%)	27 (61)	28 (57)	0.833
CRP, mg/L	2.3 (1.0–4.2)	1.6 (0.8–3.2)	0.236
DAS28(CRP)	1.6 (1.3–2.0)	1.6 (1.3–2.0)	0.939
Methotrexate use at inclusion, (%)	39 (89)	40 (82)	0.396
Disease duration, years	11 (7–19)	16 (9–23)	0.205
Duration of biologic therapy, months	55 (37–77)	68 (30–93)	0.328
Remission duration, months	17 (11–26)	20 (11–42)	0.609

Continuous variables are expressed as medians (interquartile ranges).